BR112014017673A8 - Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos - Google Patents

Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos

Info

Publication number
BR112014017673A8
BR112014017673A8 BR112014017673A BR112014017673A BR112014017673A8 BR 112014017673 A8 BR112014017673 A8 BR 112014017673A8 BR 112014017673 A BR112014017673 A BR 112014017673A BR 112014017673 A BR112014017673 A BR 112014017673A BR 112014017673 A8 BR112014017673 A8 BR 112014017673A8
Authority
BR
Brazil
Prior art keywords
tricyclic
methods
compounds
making
sulphonamide compounds
Prior art date
Application number
BR112014017673A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014017673A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
David Pallin Thomas
Joan Dyke Hazel
Mary Cramp Susan
Zahler Robert
Original Assignee
Zafgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zafgen Inc filed Critical Zafgen Inc
Publication of BR112014017673A2 publication Critical patent/BR112014017673A2/pt
Publication of BR112014017673A8 publication Critical patent/BR112014017673A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112014017673A 2012-01-18 2013-01-17 Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos BR112014017673A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261587828P 2012-01-18 2012-01-18
PCT/US2013/021919 WO2013109739A1 (en) 2012-01-18 2013-01-17 Tricyclic sulfonamide compounds and methods of making and using same

Publications (2)

Publication Number Publication Date
BR112014017673A2 BR112014017673A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
BR112014017673A8 true BR112014017673A8 (pt) 2017-07-11

Family

ID=47664425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017673A BR112014017673A8 (pt) 2012-01-18 2013-01-17 Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos

Country Status (9)

Country Link
US (1) US9359369B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2804866B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6035347B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20140112565A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013209723B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014017673A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2861390A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2014008706A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013109739A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
MX345535B (es) 2011-05-06 2017-02-03 Zafgen Inc Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
CN103764652B (zh) 2011-05-06 2016-03-23 扎夫根股份有限公司 三环吡唑磺酰胺化合物及其制备和使用方法
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
CA2873574A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
KR20150079952A (ko) 2012-11-05 2015-07-08 자프겐 인크. 트리시클릭 화합물 및 그의 제조 및 사용 방법
WO2014071368A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Methods of treating liver diseases
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
KR20150126924A (ko) 2013-03-14 2015-11-13 자프겐 인크. 신장 질환 및 기타 장애의 치료 방법
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
ES2971712T3 (es) 2017-12-22 2024-06-06 Hibercell Inc Derivados de cromenopiridina como inhibidores de la fosfatidilinositol fosfato cinasa
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
KR0138530B1 (ko) 1988-09-01 1998-05-15 우메모또 요시마사 푸마길롤 유도체
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
ATE87623T1 (de) 1989-03-06 1993-04-15 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
EP0555693B1 (en) 1992-01-30 2001-09-05 Takeda Chemical Industries, Ltd. Method of producing highly watersoluble cyclodextrin complex
EP0602586B1 (en) 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stable pharmaceutical composition of fumagillol derivatives
ES2128846T3 (es) 1995-03-27 1999-05-16 Sanofi Sa Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales.
WO1997013509A1 (fr) 1995-10-11 1997-04-17 Fujisawa Pharmaceutical Co., Ltd. Inhibiteur de permeation vasculaire
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
CA2283272A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
WO1998056372A1 (en) 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
DE69824750T2 (de) 1997-10-31 2005-07-07 Children's Medical Center Corp., Boston Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
NZ502963A (en) 1997-12-23 2002-06-28 Warner Lambert Co Thiourea and benzamide compounds and methods of treating or preventing inflammatory diseases and atherosclerosis
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
RU2278860C2 (ru) 1999-04-28 2006-06-27 Санофи-Авентис Дойчланд Гмбх Производные триарил-содержащих кислот в качестве лигандов рецепторов ппар
US6593480B2 (en) * 1999-09-01 2003-07-15 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
JP2003510359A (ja) 1999-10-01 2003-03-18 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
PE20020376A1 (es) 2000-09-29 2002-05-13 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
CN1505617A (zh) 2000-11-01 2004-06-16 ������˹ҩƷ��˾ 作为Met-AP2抑制剂的肽
CA2432181C (en) 2000-12-20 2009-11-17 Bristol-Myers Squibb Company Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
US20040116495A1 (en) 2001-03-29 2004-06-17 Marino Jr. Joseph P. Compounds and methods
US20020183242A1 (en) 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
WO2003027104A1 (en) 2001-09-27 2003-04-03 Idrtech Inc. Fumagillol derivatives and preparing method thereof
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US20040068012A1 (en) 2002-10-08 2004-04-08 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
US7304051B2 (en) 2003-08-08 2007-12-04 Janssen Pharmaceutica N.V. Quinoxaline compounds
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
BRPI0417323A (pt) 2003-12-22 2007-03-27 Memory Pharm Corp indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
JP2007537147A (ja) 2003-12-29 2007-12-20 プレーシス ファーマスーティカルズ インコーポレイテッド メチオニンアミノペプチダーゼ−２のインヒビターおよびその使用
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
AU2005245401A1 (en) 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
EP1781303A4 (en) 2004-06-30 2008-07-02 Combinatorx Inc METHOD AND REAGENTS FOR THE TREATMENT OF METABOLISM DISEASES
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006036670A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
CA2594951A1 (en) 2005-01-26 2006-08-03 Chong Kun Dang Pharmaceutical Corp. Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
US20070078172A1 (en) 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
EP1962830B1 (en) 2005-12-23 2013-03-27 GlaxoSmithKline LLC Azaindole inhibitors of aurora kinases
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
DE102007020492A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
JP2010531896A (ja) 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EP2217283A2 (en) 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
DE502008003324D1 (de) 2007-11-30 2011-06-01 Bayer Schering Pharma Ag Heteroaryl-substituierte piperidine
NZ590732A (en) 2008-07-18 2012-09-28 Zafgen Inc Methods of treating an overweight or obese subject using fumagillin
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
JP5712133B2 (ja) 2008-10-24 2015-05-07 ウェイク フォレスト ユニバーシティ 白金アクリジン抗癌化合物とその製造方法
US20120010290A1 (en) 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065883A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065881A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
US20130210821A1 (en) 2010-05-27 2013-08-15 James E. Vath Methods for Treating Obesity
JP5913310B2 (ja) * 2010-07-22 2016-04-27 ザフゲン，インコーポレイテッド 三環式化合物ならびにその作製および使用方法
WO2012051318A1 (en) 2010-10-12 2012-04-19 Zafgen Corporation Sulphonamide compounds and methods of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
WO2012075026A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of treating obesity using an effective dose of a metap-2 inhibitor
KR20140009273A (ko) 2010-11-29 2014-01-22 자프겐 인크. 6-o-(4-디메틸아미노에톡시)신나모일 푸마길롤의 비-일일 투여를 사용하는 비만의 치료
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
CN103764652B (zh) 2011-05-06 2016-03-23 扎夫根股份有限公司 三环吡唑磺酰胺化合物及其制备和使用方法
MX345535B (es) 2011-05-06 2017-02-03 Zafgen Inc Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same

Also Published As

Publication number Publication date
MX2014008706A (es) 2015-03-05
JP2015504091A (ja) 2015-02-05
US20140378462A1 (en) 2014-12-25
BR112014017673A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
WO2013109739A1 (en) 2013-07-25
AU2013209723A1 (en) 2014-08-07
JP6035347B2 (ja) 2016-11-30
CA2861390A1 (en) 2013-07-25
CN104203954A (zh) 2014-12-10
AU2013209723B2 (en) 2016-11-24
US9359369B2 (en) 2016-06-07
EP2804866A1 (en) 2014-11-26
KR20140112565A (ko) 2014-09-23
EP2804866B1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
BR112014017673A8 (pt) Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112013028665A2 (pt) compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
BR112014017780A8 (pt) Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
PH12017501306A1 (en) Inhibitors of histone demethylases
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
EA201790785A1 (ru) Производные тетрагидроизохинолина
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
GT201500069A (es) Piridinonas bicìclicas novedosas
CL2014003472A1 (es) Pro-farmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida; composicion farmaceutica que los comprende; y su uso para tratar una infeccion bacteriana.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
MX2018001733A (es) Compuestos heterocíclicos de fumagillol y métodos de elaboración y uso de los mismos.
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
CR20140553A (es) Compuestos de fenoxietil piperidina
BR112013008749A2 (pt) análogos de ciclosporina
MY203626A (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules
EA201590932A1 (ru) Композиции, содержащие вортиоксетин и донепезил
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]